{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:12:37Z","timestamp":1793592757077,"version":"4.5.0"},"reference-count":186,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and dactylitis), generally occurs in patients with psoriasis. PsA is also associated with uveitis and inflammatory bowel disease (Crohn\u2019s disease and ulcerative colitis). To capture these manifestations as well as the associated comorbidities, and to recognize their underlining common pathogenesis, the name of psoriatic disease was coined. The pathogenesis of PsA is complex and multifaceted, with an interplay of genetic predisposition, triggering environmental factors, and activation of the innate and adaptive immune system, although autoinflammation has also been implicated. Research has identified several immune-inflammatory pathways defined by cytokines (IL-23\/IL-17, TNF), leading to the development of efficacious therapeutic targets. However, heterogeneous responses to these drugs occur in different patients and in the different tissues involved, resulting in a challenge to the global management of the disease. Therefore, more translational research is necessary in order to identify new targets and improve current disease outcomes. Hopefully, this may become a reality through the integration of different omics technologies that allow better understanding of the relevant cellular and molecular players of the different tissues and manifestations of the disease. In this narrative review, we aim to provide an updated overview of the pathophysiology, including the latest findings from multiomics studies, and to describe current targeted therapies.<\/jats:p>","DOI":"10.3390\/ijms24054901","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T02:56:50Z","timestamp":1677812210000},"page":"4901","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":186,"title":["Psoriatic Arthritis: Pathogenesis and Targeted Therapies"],"prefix":"10.3390","volume":"24","author":[{"given":"Ana Bel\u00e9n","family":"Azuaga","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-0573","authenticated-orcid":false,"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Observational and Clinical Studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/BOR.0000000000000155","article-title":"Targeting Extra-Articular Manifestations in PsA: A Closer Look at Enthesitis and Dactylitis","volume":"27","author":"Siegel","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40744-020-00229-0","article-title":"Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study","volume":"7","author":"Lubrano","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities Associated with Psoriatic Arthritis: Review and Update","volume":"214","author":"Merola","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-Wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41584-021-00652-9","article-title":"Autoinflammation and Autoimmunity across Rheumatic and Musculoskeletal Diseases","volume":"17","author":"Szekanecz","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1136\/annrheumdis-2014-207190","article-title":"A Deletion at ADAMTS9-MAGI1 Locus Is Associated with Psoriatic Arthritis Risk","volume":"74","author":"Pinto","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative Genomic Profiling of Synovium versus Skin Lesions in Psoriatic Arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Anchang, C.G., Xu, C., Raimondo, M.G., Atreya, R., Maier, A., Schett, G., Zaburdaev, V., Rauber, S., and Ramming, A. (2021). The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147506"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic Heterogeneity in Psoriatic Arthritis: Towards Tissue Pathology-Based Therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"573.e1","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of Psoriatic Arthritis in the Population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","first-page":"1918","article-title":"Prevalence, Disease Manifestations, and Treatment of Psoriatic Arthritis in Western Norway","volume":"32","author":"Madland","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/annrheumdis-2013-203862","article-title":"Prevalence and Incidence Rates of Psoriatic Arthritis in Central Norway: Data from the Nord-Tr\u00f8ndelag Health Study (HUNT)","volume":"74","author":"Hoff","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","first-page":"554","article-title":"Spondyloarthropathies in Japan: Nationwide Questionnaire Survey Performed by the Japan Ankylosing Spondylitis Society","volume":"28","author":"Hukuda","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/ker370","article-title":"Epidemiology of Eight Common Rheumatic Diseases in China: A Large-Scale Cross-Sectional Survey in Beijing","volume":"51","author":"Li","year":"2012","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and Incidence of Psoriatic Arthritis: A Systematic Review and Meta-Analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/1346-8138.13342","article-title":"Epidemiological Analysis of Psoriatic Arthritis Patients in Japan","volume":"43","author":"Yamamoto","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/art.41741","article-title":"The Epidemiology of Psoriatic Arthritis over 5 Decades: A Population-Based Study","volume":"73","author":"Karmacharya","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","article-title":"Gender Difference in Disease Expression, Radiographic Damage and Disability among Patients with Psoriatic Arthritis","volume":"72","author":"Eder","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/rheumatology\/kew375","article-title":"The Psoriatic Arthritis Registry of Turkey: Results of a Multicentre Registry on 1081 Patients","volume":"56","author":"Kalyoncu","year":"2017","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105177","DOI":"10.1016\/j.jbspin.2021.105177","article-title":"Gender-Related Differences in Disease Activity and Clinical Features in Patients with Peripheral Psoriatic Arthritis: A Multi-Center Study","volume":"88","author":"Gezer","year":"2021","journal-title":"Jt. Bone Spine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","article-title":"A 2-Year Observational Study on Treatment Targets in Psoriatic Arthritis Patients Treated with TNF Inhibitors","volume":"36","author":"Chimenti","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and Predictors of Tumour Necrosis Factor Inhibitor Persistence in Psoriatic Arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s10067-020-05027-1","article-title":"Retention Rates and Identification of Factors Associated with Anti-TNF\u03b1, Anti-IL17, and Anti-IL12\/23R Agents Discontinuation in Psoriatic Arthritis Patients: Results from a Real-World Clinical Setting","volume":"39","author":"Navarini","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_28","first-page":"19","article-title":"Retrospective Evaluation of Patient Profiling and Effectiveness of Apremilast in an Italian Multicentric Cohort of Psoriatic Arthritis Patients","volume":"38","author":"Favalli","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex Differences in Immune Responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","first-page":"813","article-title":"Serum BAFF Strongly Correlates with PsA Activity in Male Patients Only\u2014Is There a Role for Sex Hormones?","volume":"28","author":"Pongratz","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3899\/jrheum.080691","article-title":"Time Trends in Epidemiology and Characteristics of Psoriatic Arthritis Over 3 Decades: A Population-Based Study","volume":"36","author":"Wilson","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.semarthrit.2018.08.005","article-title":"Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis","volume":"48","author":"Polachek","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.58.4.226","article-title":"Clinical and Laboratory Manifestations of Elderly Onset Psoriatic Arthritis: A Comparison with Younger Onset Disease","volume":"58","author":"Punzi","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e7833","DOI":"10.1097\/MD.0000000000007833","article-title":"Characteristics of Turkish Patients with Elderly Onset Psoriatic Arthritis: A Retrospective Cohort Study","volume":"96","author":"Kobak","year":"2017","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.55563\/clinexprheumatol\/ert0p7","article-title":"Disease Characteristics of Psoriatic Arthritis Patients May Differ According to Age at Psoriasis Onset: Cross-Sectional Data from the Psoriatic Arthritis-International Database","volume":"39","author":"Bilgin","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic Arthritis from a Mechanistic Perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0198-8859(03)00162-9","article-title":"HLA Is a Candidate Region for Psoriatic Arthritis: Evidence for Excessive HLA Sharing in Sibling Pairs","volume":"64","author":"Gladman","year":"2003","journal-title":"Hum. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ard.2008.089367","article-title":"Familial Aggregation of Psoriatic Arthritis","volume":"68","author":"Chandran","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1038\/s41598-020-61981-5","article-title":"Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis Vulgaris (PsV)","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of Pathogenesis in Psoriatic Arthritis: Genotype Determines Clinical Phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajhg.2014.07.002","article-title":"Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes","volume":"95","author":"Okada","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense Genotyping of Immune-Related Susceptibility Loci Reveals New Insights into the Genetics of Psoriatic Arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fgene.2019.00304","article-title":"Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC","volume":"10","author":"Patrick","year":"2019","journal-title":"Front. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/annrheumdis-2019-215355","article-title":"Inflammatory Cytokines Shape a Changing DNA Methylome in Monocytes Mirroring Disease Activity in Rheumatoid Arthritis","volume":"78","author":"Li","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/art.41885","article-title":"Prediction of the Progression of Undifferentiated Arthritis to Rheumatoid Arthritis Using DNA Methylation Profiling","volume":"73","author":"Niemantsverdriet","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e158783","DOI":"10.1172\/jci.insight.158783","article-title":"The Synovial and Blood Monocyte DNA Methylomes Mirror Prognosis, Evolution, and Treatment in Early Arthritis","volume":"7","author":"Ciudad","year":"2022","journal-title":"JCI Insight"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41584-022-00890-5","article-title":"Progress Continues in Prediction of the Response to Treatment of RA","volume":"19","author":"Lewis","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jdermsci.2022.11.001","article-title":"DNA Methylation Markers in Peripheral Blood for Psoriatic Arthritis","volume":"108","author":"Deng","year":"2022","journal-title":"J. Dermatol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"746145","DOI":"10.3389\/fcell.2021.746145","article-title":"DNA Methylation Patterns in CD8+ T Cells Discern Psoriasis From Psoriatic Arthritis and Correlate With Cutaneous Disease Activity","volume":"9","author":"Charras","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","article-title":"Epithelial Toll-like Receptors and Their Role in Gut Homeostasis and Disease","volume":"17","author":"Abreu","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the Microbiota in Immunity and Inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-Microbe Interactions Have Shaped the Genetic Architecture of Inflammatory Bowel Disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 Major Types of Innate and Adaptive Cell-Mediated Effector Immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the Gut-Joint Axis: Links between Gut Inflammation and Spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysbiosis and Zonulin Upregulation Alter Gut Epithelial and Vascular Barriers in Patients with Ankylosing Spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Boix-Amor\u00f3s, A., Badri, M.H., Manasson, J., Blank, R.B., Haberman, R.H., Neimann, A.L., Girija, P.V., Jimenez Hernandez, A., Heguy, A., and Koralov, S. (2022). Alterations in the Cutaneous Microbiome of Patients with Psoriasis and Psoriatic Arthritis Reveal Similarities between Non-Lesional and Lesional Skin. Ann. Rheum. Dis., online first.","DOI":"10.1136\/ard-2022-223389"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41584-019-0364-x","article-title":"Tendon and Ligament Mechanical Loading in the Pathogenesis of Inflammatory Arthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1038\/s41467-018-06933-4","article-title":"Mechanical Strain Determines the Site-Specific Localization of Inflammation and Tissue Damage in Arthritis","volume":"9","author":"Gaublomme","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","article-title":"Classification of Inflammatory Arthritis by Enthesitis","volume":"352","author":"McGonagle","year":"1998","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of Myeloid Cells in the Human Enthesis as the Main Source of Local IL-23 Production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","article-title":"Physical Trauma Recorded in Primary Care Is Associated with the Onset of Psoriatic Arthritis among Patients with Psoriasis","volume":"76","author":"Thorarensen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/ker349","article-title":"Differences in Body Mass Index among Individuals with PsA, Psoriasis, RA and the General Population","volume":"51","author":"Bhole","year":"2012","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","article-title":"Body Mass Index, Abdominal Fatness, Weight Gain and the Risk of Psoriasis: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies","volume":"33","author":"Aune","year":"2018","journal-title":"Eur. J. Epidemiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and Psoriatic Arthritis: From Pathogenesis to Clinical Outcome and Management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatology"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Singh, S., Facciorusso, A., Singh, A.G., van de Casteele, N., Zarrinpar, A., Prokop, L.J., Grunvald, E.L., Curtis, J.R., and Sandborn, W.J. (2018). Obesity and Response to Anti-Tumor Necrosis Factor-\u03b1 Agents in Patients with Select Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195123"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/rheumatology\/keaa179","article-title":"The Impact of Smoking on Prevalence of Psoriasis and Psoriatic Arthritis","volume":"59","author":"Gazel","year":"2020","journal-title":"Rheumatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2017-211625","article-title":"Smoking Paradox in the Development of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study","volume":"77","author":"Nguyen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"152146","DOI":"10.1016\/j.semarthrit.2022.152146","article-title":"Smoking and Alcohol Consumption Are Associated with Peripheral Musculoskeletal Involvement in Patients with Spondyloarthritis (Including Psoriatic Arthritis). Results from the ASAS-PerSpA Study","volume":"58","author":"Granados","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.1992.01680110049004","article-title":"The Role of Streptococcal Infection in the Initiation of Guttate Psoriasis","volume":"128","author":"Telfer","year":"1992","journal-title":"Arch. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/1529-0131(199910)42:10<2055::AID-ANR5>3.0.CO;2-A","article-title":"V2 regions of 16s ribosomal rna used as a molecular marker for the species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis","volume":"42","author":"Wang","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/rheumatology\/keac253","article-title":"Strong Site-Specific Association of Pharyngeal Cultures with the Onset of Psoriatic Arthritis and Psoriasis, Regardless of Pathogen","volume":"62","author":"Thrastardottir","year":"2023","journal-title":"Rheumatology"},{"key":"ref_72","first-page":"374","article-title":"Toll-like Receptor-2 Expression Is Upregulated in Antigen-Presenting Cells from Patients with Psoriatic Arthritis: A Pathogenic Role for Innate Immunity?","volume":"34","author":"Candia","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1189\/jlb.0110057","article-title":"A \u201cToll\u201d for Th17 Cell Expansion","volume":"88","author":"Davila","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10870","DOI":"10.1038\/s41598-019-47310-5","article-title":"Increased Frequency of Activated CD8+ T Cell Effectors in Patients with Psoriatic Arthritis","volume":"9","author":"Diani","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients with Psoriatic Arthritis and Correlate with Disease Activity and Joint Damage Progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbrc.2009.05.140","article-title":"TGF-Beta Is Necessary for Induction of IL-23R and Th17 Differentiation by IL-6 and IL-23","volume":"386","author":"Morishima","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The Pathogenesis of Psoriatic Arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical Role of Interleukin (IL)-17 in Inflammatory and Immune Disorders: An Updated Review of the Evidence Focusing in Controversies","volume":"19","author":"Puig","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.20181","article-title":"Antiangiogenic Effects of Anti-Tumor Necrosis Factor Alpha Therapy with Infliximab in Psoriatic Arthritis","volume":"50","author":"Pablos","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 Axis in Psoriatic Arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 Induces Spondyloarthropathy by Acting on ROR-\u0393t+ CD3+CD4-CD8- Entheseal Resident T Cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"key":"ref_83","first-page":"1092","article-title":"Th17 Cytokines Interleukin (IL)-17 and IL-22 Modulate Distinct Inflammatory and Keratinocyte-Response Pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Vi\u010di\u0107, M., Ka\u0161telan, M., Brajac, I., Soto\u0161ek, V., and Massari, L.P. (2021). Current Concepts of Psoriasis Immunopathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111574"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/rheumatology\/kev330","article-title":"Immunopathology of Synovitis: From Histology to Molecular Pathways","volume":"55","author":"Baeten","year":"2016","journal-title":"Rheumatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/art.1780360705","article-title":"Reduced Synovial Membrane Macrophage Numbers, ELAM-1 Expression, and Lining Layer Hyperplasia in Psoriatic Arthritis as Compared with Rheumatoid Arthritis","volume":"36","author":"Veale","year":"1993","journal-title":"Arthritis Rheum."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/art.30433","article-title":"Synovial Fibroblast Hyperplasia in Rheumatoid Arthritis: Clinicopathologic Correlations and Partial Reversal by Anti-Tumor Necrosis Factor Therapy","volume":"63","author":"Izquierdo","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"656667","DOI":"10.3389\/fmed.2021.656667","article-title":"Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis","volume":"8","author":"Cuervo","year":"2021","journal-title":"Front. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib Regulates Synovial Inflammation in Psoriatic Arthritis, Inhibiting STAT Activation and Induction of Negative Feedback Inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1002\/art.20476","article-title":"Diagnostic Classification of Spondylarthropathy and Rheumatoid Arthritis by Synovial Histopathology: A Prospective Study in 154 Consecutive Patients","volume":"50","author":"Baeten","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/path.1044","article-title":"Macrophages Expressing the Scavenger Receptor CD163: A Link between Immune Alterations of the Gut and Synovial Inflammation in Spondyloarthropathy","volume":"196","author":"Baeten","year":"2002","journal-title":"J. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/ard.2004.024430","article-title":"P53 Expression in Rheumatoid and Psoriatic Arthritis Synovial Tissue and Association with Joint Damage","volume":"64","author":"Salvador","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"613975","DOI":"10.3389\/fimmu.2020.613975","article-title":"GM-CSF Expression and Macrophage Polarization in Joints of Undifferentiated Arthritis Patients Evolving to Rheumatoid Arthritis or Psoriatic Arthritis","volume":"11","author":"Cuervo","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"722349","DOI":"10.3389\/fimmu.2021.722349","article-title":"CD209\/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration, and Therapeutic Targeting","volume":"12","author":"Marzaioli","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard.2006.062042","article-title":"Ectopic Lymphoid Neogenesis in Psoriatic Arthritis","volume":"66","author":"Santiago","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/art.40830","article-title":"Identification of Novel Autoantibodies Associated With Psoriatic Arthritis","volume":"71","author":"Yuan","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jalm\/jfab120","article-title":"Autoantibodies in Psoriatic Disease","volume":"7","author":"Koussiouris","year":"2022","journal-title":"J. Appl. Lab. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.141577","article-title":"Differential Antigen-Presenting B Cell Phenotypes from Synovial Microenvironment of Patients with Rheumatoid and Psoriatic Arthritis","volume":"42","author":"Bustabad","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/rheumatology\/kez204","article-title":"Apremilast Increases IL-10-Producing Regulatory B Cells and Decreases Proinflammatory T Cells and Innate Cells in Psoriatic Arthritis and Psoriasis","volume":"58","author":"Mavropoulos","year":"2019","journal-title":"Rheumatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","article-title":"de Synovial Histopathology of Psoriatic Arthritis, Both Oligo- and Polyarticular, Resembles Spondyloarthropathy More than It Does Rheumatoid Arthritis","volume":"7","author":"Kruithof","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/art.11331","article-title":"Turnover of Type II Collagen and Aggrecan in Cartilage Matrix at the Onset of Inflammatory Arthritis in Humans: Relationship to Mediators of Systemic and Local Inflammation","volume":"48","author":"Fraser","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally Distinct Disease-Associated Fibroblast Subsets in Rheumatoid Arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/annrheumdis-2021-221761","article-title":"Distinct Stromal and Immune Cell Interactions Shape the Pathogenesis of Rheumatoid and Psoriatic Arthritis","volume":"81","author":"Floudas","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Rauber, S., Mohammadian, H., Schmidkonz, C., Atzinger, A., Soare, A., Maschauer, S., Treutlein, C., Angeli, M., Raimondo, M.G., and Xu, C. (2023). Molecular Imaging with Fibroblast Activation Protein Tracers Depicts Inflammatory Joint Damage and Its Transition to Resolution of Inflammation. bioRxiv.","DOI":"10.1101\/2023.01.17.524425"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-Cell Sequencing Reveals Clonal Expansions of pro-Inflammatory Synovial CD8 T Cells Expressing Tissue-Homing Receptors in Psoriatic Arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/annrheumdis-2018-214138","article-title":"Association of Synovial Tissue Polyfunctional T-Cells with DAPSA in Psoriatic Arthritis","volume":"78","author":"Wade","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.064691","article-title":"Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-Hexafluoro-2-Hydroxypropan-2-Yl)-Phenyl]-Ethyl}-3-Methylpyridine-1-Oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor","volume":"310","author":"Claveau","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-Inflammatory Activities of CAMP-Elevating Agents: Enhancement of IL-10 Synthesis and Concurrent Suppression of TNF Production","volume":"63","author":"Eigler","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor, in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase III, Randomized, Controlled Trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and Safety of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate-to-severe Plaque Psoriasis over 52 Weeks: A Phase III, Randomized Controlled Trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Extended Report: Treatment of Psoriatic Arthritis in a Phase 3 Randomised, Placebo-Controlled Trial with Apremilast, an Oral Phosphodiesterase 4 Inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Extended Report: Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement: A Phase III, Randomised, Controlled Trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast Monotherapy in DMARD-Naive Psoriatic Arthritis Patients: Results of the Randomized, Placebo-Controlled PALACE 4 Trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of Certolizumab Pegol on Signs and Symptoms in Patients with Psoriatic Arthritis: 24-Week Results of a Phase 3 Double-Blind Randomised Placebo-Controlled Study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of Psoriatic Arthritis with Anti-TNF Agents: A Systematic Review and Meta-Analysis of Efficacy, Effectiveness and Safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3310\/hta15100","article-title":"Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation","volume":"15","author":"Rodgers","year":"2011","journal-title":"Health Technol. Assess"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.12045","article-title":"Direct and Indirect Comparison of the Efficacy and Safety of Adalimumab, Etanercept, Infliximab and Golimumab in Psoriatic Arthritis","volume":"38","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_123","first-page":"31","article-title":"Etanercept and Infliximab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol. Assess"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the Risk of Developing Uveitis in Patients Initiating Anti-Tumor Necrosis Factor Therapy for Ankylosing Spondylitis: An Analysis of a Large US Claims Database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for Cytotoxic Effects of Anti-Tumor Necrosis Factor Agents on Transmembrane Tumor Necrosis Factor Alpha-Expressing Cells: Comparison among Infliximab, Etanercept, and Adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of Infections Using Anti-TNF Agents in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative Risk of Serious Infections among Real-World Users of Biologics for Psoriasis or Psoriatic Arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of Demyelination Occurring during Anti-TNF-\u03b1 Therapy: A French National Survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Leone, G.M., Mangano, K., Petralia, M.C., Nicoletti, F., and Fagone, P. (2023). Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041630"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled PSUMMIT 1 Trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and Safety of the Anti-IL-12\/23 P40 Monoclonal Antibody, Ustekinumab, in Patients with Active Psoriatic Arthritis despite Conventional Non-Biological and Biological Anti-Tumour Necrosis Factor Therapy: 6-Month and 1-Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled, Randomised PSUMMIT 2 Trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-020-05057-9","article-title":"Effectiveness of Ustekinumab in Patients with Psoriatic Arthritis in a Real-World, Multicenter Study","volume":"39","author":"Azuaga","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in Patients with Active Psoriatic Arthritis Who Were Biologic-Naive or Had Previously Received TNF\u03b1 Inhibitor Treatment (DISCOVER-1): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in Biologic-Naive Patients with Active Psoriatic Arthritis (DISCOVER-2): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results through One Year of a Phase IIIb, Randomised, Controlled Study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Randomised, Double-Blind, Phase 3 KEEPsAKE 1 Trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Randomised, Double-Blind, Phase 3 KEEPsAKE 2 Trial","volume":"81","author":"Papp","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_139","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04314544, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314544."},{"key":"ref_140","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04314531, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314531."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and Safety of Tildrakizumab in Patients with Active Psoriatic Arthritis: Results of a Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose, 52-Week Phase IIb Study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Dose-Finding Phase 2 Study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an Interleukin-17A Antagonist in the Treatment of Ankylosing Spondylitis or Radiographic Axial Spondyloarthritis in Patients Previously Untreated with Biological Disease-Modifying Anti-Rheumatic Drugs (COAST-V): 16 Week Results of a Phase 3 Randomised, Double-Blind, Active-Controlled and Placebo-Controlled Trial","volume":"392","author":"Dougados","year":"2018","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of Circulating Interleukin-17-Secreting Interleukin-23 Receptor-Positive \u03b3\/\u03b4 T Cells in Patients with Active Ankylosing Spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"637829","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 Pathway in Rheumatic Diseases: An Overview","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of Guselkumab on Axial Involvement in Patients with Active Psoriatic Arthritis and Sacroiliitis: A Post-Hoc Analysis of the Phase 3 DISCOVER-1 and DISCOVER-2 Studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_149","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04929210, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04929210."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, in Patients with Psoriatic Arthritis (FUTURE 2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and Safety of Secukinumab Administration by Autoinjector in Patients with Psoriatic Arthritis: Results from a Randomized, Placebo-Controlled Trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and Safety of Subcutaneous Secukinumab 150 Mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_154","first-page":"890","article-title":"Secukinumab Improves Active Psoriatic Arthritis Symptoms and Inhibits Radiographic Progression: Primary Results from the Randomised, Double-Blind, Phase III FUTURE 5 Study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus Adalimumab for Treatment of Active Psoriatic Arthritis (EXCEED): A Double-Blind, Parallel-Group, Randomised, Active-Controlled, Phase 3b Trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-Term Safety of Secukinumab Over Five Years in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an Interleukin-17A Specific Monoclonal Antibody, for the Treatment of Biologic-Naive Patients with Active Psoriatic Arthritis: Results from the 24-Week Randomised, Double-Blind, Placebo-Controlled and Active (Adalimumab)-Controlled Period of the Phase III Trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the Treatment of Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the 24-Week Randomised, Double-Blind, Placebo-Controlled Period of the SPIRIT-P2 Phase 3 Trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Na\u00efve Patients with Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The Role of IL-17A in Axial Spondyloarthritis and Psoriatic Arthritis: Recent Advances and Controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor-\u03b1 Inhibitors: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in Patients with Psoriatic Arthritis, Naive to Biologic Treatment: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e15105","DOI":"10.1111\/dth.15105","article-title":"Three-Year U.S. Pharmacovigilance Report of Brodalumab","volume":"34","author":"Lebwohl","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn\u2019s Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients with Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab Failure in Crohn\u2019s Disease: The Yeast Connection?","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK Selectivity and the Implications for Clinical Inhibition of Pharmacodynamic Cytokine Signalling by Filgotinib, Upadacitinib, Tofacitinib and Baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in Patients with Psoriatic Arthritis and an Inadequate Response to Non-Biological Therapy: 56-Week Data from the Phase 3 SELECT-PsA 1 Study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for Psoriatic Arthritis Refractory to Biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor, in Patients with Active Psoriatic Arthritis (EQUATOR): Results from a Randomised, Placebo-Controlled, Phase 2 Trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"ref_174","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04115748, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04115748."},{"key":"ref_175","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04115839, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04115839."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_177","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04908202, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04908202."},{"key":"ref_178","unstructured":"ClinicalTrials.Gov (2022, December 10). Identifier: NCT04908189, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04908189."},{"key":"ref_179","first-page":"1009","article-title":"Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2\/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial","volume":"73","author":"Mease","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus Tocilizumab in Anti-TNF Inadequate Responder Patients with Rheumatoid Arthritis (R4RA): 16-Week Outcomes of a Stratified, Biopsy-Driven, Multicentre, Open-Label, Phase 4 Randomised Controlled Trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus Tocilizumab in Rheumatoid Arthritis: Synovial Biopsy-Based Biomarker Analysis of the Phase 4 R4RA Randomized Trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat. Med."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Gurke, R., Bendes, A., Bowes, J., Koehm, M., Twyman, R.M., Barton, A., Elewaut, D., Goodyear, C., Hahnefeld, L., and Hillenbrand, R. (2022). Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102387"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41584-022-00748-w","article-title":"HIPPOCRATES: Improving Diagnosis and Outcomes in Psoriatic Arthritis","volume":"18","author":"FitzGerald","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Winthrop, K.L., Isaacs, J.D., Mease, P.J., Boumpas, D.T., Baraliakos, X., Gottenberg, J.-E., Siebert, S., Mosca, M., Basu, N., and Orange, D. (2023). Unmet Need in Rheumatology: Reports from the Advances in Targeted Therapies Meeting, 2022. Ann. Rheum. Dis., online first.","DOI":"10.1136\/ard-2022-223528"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2967\/jnumed.122.263922","article-title":"FAPI PET Opens a New Window to Understanding Immune-Mediated Inflammatory Diseases","volume":"63","author":"Kuwert","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of Guselkumab, a Selective IL-23 Inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk Cohort (PAMPA): Protocol of a Randomised, Double-Blind, Placebo Controlled Multicentre Trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4901\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:46:50Z","timestamp":1760122010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":186,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24054901"],"URL":"https:\/\/doi.org\/10.3390\/ijms24054901","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}